Clinical trial
Phase 2 Study Evaluating the Safety and Efficacy of Eloxatin (Oxaliplatin) and Docetaxel as First-line Therapy of Stage IV or IIIB Unresectable Non-Small Cell Lung Cancer
NCT00145418 is registered in ClinicalTrials.gov with Oncology Specialists, S.C. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study Evaluating the Safety and Efficacy of Eloxatin (Oxaliplatin) and Docetaxel as First-line Therapy of Stage IV or IIIB Unresectable Non-Small Cell Lung Cancer
- Lead sponsor
- Oncology Specialists, S.C.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 28, 2005
- Completion date
- March 31, 2010
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.